Brief: Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals Holdings

15/05/2024 13:23

May 15 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
 RVPH.O :
    * REVIVA ANNOUNCES ENROLLMENT UPDATE FOR OPEN LABEL
EXTENSION
STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. -BRILAROXAZINE IS
GENERALLY WELL TOLERATED TO DATE IN PATIENTS WITH ACUTE AND
STABLE SCHIZOPHRENIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. -358 ENROLLED AND
223
PATIENTS CURRENTLY ON TREATMENT ACROSS SITES IN USA, EUROPE AND
ASIA
    * REVIVA PHARMACEUTICALS HOLDINGS, INC. -TOPLINE DATA FROM
1-YEAR
OPEN-LABEL EXTENSION (OLE) TRIAL EXPECTED IN Q4 2024

Source text for Eikon:  ID:nGNXdSxtG 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))